Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 18Neoplasm Metastasis 14Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Recurrence 9Ovarian Neoplasms 7Skin Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Renal Cell 5Carcinoma, Basal Cell 5Triple Negative Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Merkel Cell 3Adenocarcinoma 3Sarcoma 2Pancreatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Glioma 2

Interventions

cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Cutaneous Squamous Cell Carcinoma × cemiplimab × Clear all
NCT03969004 2026-03-27

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
415 enrolled 1 FDA
Dermatologic

Cutaneous Squamous Cell Carcinoma

NCT04154943 2025-12-23

Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 2 Completed
79 enrolled 16 charts
Dermatologic

Cutaneous Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡